全文获取类型
收费全文 | 866篇 |
免费 | 32篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 9篇 |
妇产科学 | 5篇 |
基础医学 | 85篇 |
口腔科学 | 3篇 |
临床医学 | 353篇 |
内科学 | 157篇 |
皮肤病学 | 5篇 |
神经病学 | 40篇 |
特种医学 | 3篇 |
外科学 | 171篇 |
综合类 | 13篇 |
预防医学 | 18篇 |
眼科学 | 1篇 |
药学 | 24篇 |
肿瘤学 | 12篇 |
出版年
2023年 | 10篇 |
2022年 | 5篇 |
2021年 | 12篇 |
2020年 | 11篇 |
2019年 | 19篇 |
2018年 | 11篇 |
2017年 | 14篇 |
2016年 | 17篇 |
2015年 | 21篇 |
2014年 | 26篇 |
2013年 | 44篇 |
2012年 | 64篇 |
2011年 | 68篇 |
2010年 | 25篇 |
2009年 | 20篇 |
2008年 | 43篇 |
2007年 | 52篇 |
2006年 | 58篇 |
2005年 | 46篇 |
2004年 | 41篇 |
2003年 | 54篇 |
2002年 | 54篇 |
2001年 | 32篇 |
2000年 | 27篇 |
1999年 | 23篇 |
1998年 | 7篇 |
1997年 | 5篇 |
1996年 | 3篇 |
1994年 | 3篇 |
1993年 | 6篇 |
1992年 | 18篇 |
1991年 | 9篇 |
1990年 | 8篇 |
1989年 | 7篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1985年 | 4篇 |
1984年 | 2篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1975年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 4篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1967年 | 1篇 |
1965年 | 1篇 |
1939年 | 1篇 |
排序方式: 共有902条查询结果,搜索用时 31 毫秒
1.
M C Mingari A Poggi R Bellomo N Pella L Moretta 《International Journal of Clinical & Laboratory Research》1991,21(2):176-178
Purified CD3-4- thymocyte populations were cultured in the presence of interleukin-2 (IL-2) and peripheral blood lymphocytes (PBL) and/or tumor cell lines as a source of irradiated feeder cells. Maximal cell proliferation was obtained in the presence of a mixture of H9 leukemic cells and normal PBL. More importantly, under these culture conditions, 30%-50% of these cells were found to express CD16 surface antigen after 1-2 weeks of culture. Similar proportions of CD16+ cells could be detected in CD3-4- thymocyte populations that had been further depleted of CD16+ cells. Cloning of CD3-4-16- thymocytes under limiting dilution conditions resulted, in the presence of H9 cells, in more than 50% of CD16+ clones (cloning efficiency 3%-8%). Since some of the surface CD3- clones expressed cytoplasmic CD3 antigen, it has been possible to identify four distinct phenotypic groups of clones (CD16+cyCD3+, CD16+cyCD3-, CD16-cyCD3+, CD16-cyCD3-). Independently of their phenotype, all thymus-derived CD3- clones expressed a strong cytolytic activity against natural killer (NK)-sensitive and NK-resistant tumour target cells. In addition, following stimulation with phytohemagglutinin (PHA) and phorbol 12-myristate 13-acetate (or PHA alone) all clones released interferon-gamma and tumour necrosis factor-alpha, but not IL-2. Taken together, our data provide evidence that cells which share their phenotypic and functional properties with CD3-CD16+ NK cells can be derived from thymic precursors. 相似文献
2.
3.
L. Morino F. Bellomo P. Milano L. Bertignone M. Sabra 《Journal of orthopaedics and traumatology》2002,2(2):59-62
The authors, reviewing the international literature with their clinical experience developed in reconstructive surgery of
acetabular defects due to aseptic loosening of acetabular cups, suggest their guidelines to the right use of acetabular reinforcement
rings.
Received: 8 September 2001/Accepted: 4 November 2001 相似文献
4.
5.
Ethics roundtable debate: Patients and surrogates want 'everything done' – what does 'everything' mean? 下载免费PDF全文
Christopher Doig Holt Murray Rinaldo Bellomo Michael Kuiper Rubens Costa Elie Azoulay David Crippen 《Critical care (London, England)》2006,10(5):231
Highly complex and specialized care plans sometimes overwhelm the comprehension of patients and families. Many optimistic surrogates of critically ill patients err on the side of desiring that everything be done but with a nebulous idea of what 'everything' entails. Physicians must work closely to educate surrogates as to the benefits versus the risks of treatment. Our roundtable experts ponder the question of whether providers possess the authority to interpret unilaterally the nature of requests for everything. 相似文献
6.
7.
Spartaco Bellomo 《Emerging infectious diseases》2005,11(6):985-987
8.
Lee WC Uchino S Fealy N Baldwin I Panagiotopoulos S Goehl H Morgera S Neumayer HH Bellomo R 《The International journal of artificial organs》2004,27(1):24-28
BACKGROUND AND OBJECTIVES: The removal of cytokines by standard hemofiltration is limited. Super high flux membranes may significantly improve removal even when used in dialysis mode. We sought to measure cytokine clearance using a large surface super high-flux membrane and a standard hemodialysis setting. SETTING: ICU laboratory of a tertiary institution. SUBJECTS: Six healthy volunteers. METHODS: Blood form healthy volunteers was incubated for 4 hours with E. coli endotoxin to stimulate cytokine production. Cytokine containing blood was then circulated through a dialysis circuit at 3 different dialysate flow rates. Blood and dialysate were sampled for cytokine and albumin measurements and calculation of clearances. RESULTS: Super high-flux dialysis achieved high median cytokine clearances (IL-1 clearance of 106 ml/min, IL-6 clearance of 66.8 ml/min, IL-8 clearance of 61.7 ml/min and TNF clearance of 36.1 ml/min). Increasing dialysate flow rate from 300 to 500 ml/min did not significantly increase cytokine clearances. Albumin clearances however were between 2.7 and 5.4 ml/min. CONCLUSIONS: Cytokine dialysis is feasible at high dialysate flow rates yielding high cytokine clearances. Albumin loss, however, is appreciable and may require separate supplementation in the clinical setting. 相似文献
9.
10.
Tan HK Bellomo R M'Pis DA Ronco C 《The International journal of artificial organs》2001,24(4):186-191
BACKGROUND: Achieving "adequacy of dialysis" includes the maintenance of normal serum phosphate concentrations and is an important therapeutic goal in the treatment of acute renal failure (ARF). It is unknown whether this goal is best achieved with intermittent or continuous renal replacement therapy. METHODS: We compared the effects of continuous veno-venous hemodiafiltration (CVVHDF) and intermittent hemodialysis (IHD) on serum phosphate concentrations using daily morning blood tests in 88 consecutive intensive care patients half of which were treated with IHD and half with CRRT RESULTS: Mean patient age was 54+/-14 years for IHD and 60+/-14 years for CVVHDF (NS). However, patients who received CVVHDF were more critically ill (mean APACHE II scores: 24.4+/-5.1 for IHD vs. 29.2+/-5.7 for CVVHDF, p<0.003). Before treatment, the serum phosphate concentration was 2.04+/-0.16 mmoll L for IHD and 1.96+/-0.17 mmoll L for CVVHDF (NS), with abnormal values in 79.4% of IHD patients and in 64.8% of CVVHDF patients (NS). During treatment, CVVHDF induced a greater reduction in serum phosphate (p=0.02) during the first 48 hours and conferred superior subsequent control of hyperphosphatemia (achieved in 64.6% of observations during CVVHDF vs. 41.8% during IHD; p<0.0001). The serum phosphate concentration was also more likely to be within the normal range during CVVHDF (55.3% vs.36.2%; p<0.0001). There was a trend toward more frequent hypophosphatemia (9.3% vs. 5.6%; P<0.1) during CVVHDF CONCLUSIONS: Abnormal serum phosphate concentrations are frequent in ARF patients before and during renal replacement, however, normalization of phosphatemia is achieved more frequently with CVVHDF. 相似文献